HPV- genetic test (14 genotypes) qualitatively

• The collected material must be accompanied by a form:
  Consent for HPV genetic testing from liquid cytology (downloadable at www.luxmedlublin.pl - For the Patient - Patient Essentials - Downloadable forms).
• Moisturizers, intimate hygiene products, contraceptive gels (with the exception of a gel called Advantage - S ® Bioadhesive Contraceptive Gel) do not interfere with the test.

• The test should not be performed:
  - during menstruation,
  - during treatment with antibiotics,
  - during treatment with vaginal preparations (globules, creams),
  - when irrigations are used,
  - within 48 hours after the last sexual intercourse.
  On the day of the test, the genital area should be washed without using soap or intimate hygiene gels.
  If treatment has been used, a 3-5 day break is recommended between the end of treatment
  and the performance of the test.
• HPV testing can be performed up to 4 weeks after collection of material for liquid cytology.
• The test material in women is a cervical swab.

• The test material is a swab from the genital groove.
  If treatment was used, it is recommended that there be a 3-5 day break between the end of treatment,
  and the performance of the test.
  Before taking the material for the test:
  - do not use antibiotics, steroids, medicated creams,
  - do not wash genitals for at least 48 hours (72 hours recommended to increase the effectiveness of virus detection),
  - do not have sex for at least 24 hours.

Samples brought from outside are not accepted for testing.
It is necessary to attach a document-"Referral and consent for genetic testing(HPV,Chlamydia trachomatis) LUXMED. Available in the Patient's Essentials-Downloadable forms.

The test is intended to detect the presence of DNA of highly oncogenic types of the HPV virus. It is performed using the polymerase chain reaction (PCR) method in real time (Rael Time PCR).
The test detects HPV type 16 and 18 DNA, and 12 genotypes from the group with high oncogenic potential, i.e.: 31,33,35,39,45,51,52,56,58,59,66,68, without their genotyping. Which means that the detection of the presence of HPV from this group (Other) is reported in the result as "DETECTED", without the possibility of indicating specifically which of these genotypes is present in the patient's material.
HPV (Human Papillomavirus) is a human papillomavirus that plays a very important role in the development of many diseases. In most cases, it is the cause of benign pathologies, but some genotypes cause neoplastic transformation associated with the development of cancer and precancerous conditions. The HPV virus plays a particularly important role in the development of cervical cancer in women.
Epidemiological data indicate that cervical cancer is the second most common malignant tumor in women.
According to statistics, approximately 75% of sexually active women are infected with HPV at some point in their lives. In 80% of cases, the virus usually resolves spontaneously after a few months, but the chronic form affects 20% of women. Among this group, persistent infection caused by HPV increases the risk of cervical cancer almost 7-fold. Cervical cancer mainly affects women aged 40 to 60, although it can also occur much earlier. Therefore, every woman aged 15 to 64 should undergo the test. In countries where universal screening systems aimed at detecting HPV infections and detecting cervical cancer have been implemented, mortality due to cervical cancer has decreased by several dozen percent.
A frequently performed cytological test is a simple and effective screening method, but it does not detect all cases of cervical cancer, especially pre-cancerous conditions, and it does not detect the HPV infection itself, which is associated with the possibility of early prevention.
Pathologies caused by human papillomavirus are:
– skin lesions (warts, ungualsquamous cell carcinoma)
– lesions located on mucous membranes (respiratory tract warts, laryngeal papillomatosis, laryngeal cancer, conjunctival cancer, oral cancer, esophageal cancer)
– changes in the genital organs and anus (condyloma acuminata, Bowen’s disease, genital intraepithelial plasia, vulvar cancer, vaginal cancer, cervical cancer, anal cancer).
Early and accurate identification of the HPV virus (both high- and low-oncogenic types) enables proper treatment and prevention of the disease. Infection with any of the high-oncogenic HPV types poses a high risk of developing cancer.

Enter a one-time code:Show
An invalid code has been entered. Please try again.